How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/synergy-for-nosocomial-pneumonia-due-to-pseudomonas-aeruginosa.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Synergy for Nosocomial Pneumonia due to Pseudomonas Aeruginosa — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Synergy for Nosocomial Pneumonia due to Pseudomonas Aeruginosa (disease) competitive landscape: 5 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

5 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Synergy for Nosocomial Pneumonia due to Pseudomonas Aeruginosa, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Levaquin	levofloxacin	Generic (originally Daiichi Sankyo/J&J)	Fluoroquinolone Antibacterial [EPC]	CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2	1996-12-20
Vantobra	Tobramycin Sulfate	Pfizer	tobramycin	Taste receptor type 2 member 20	1974-01-01
Tobi	tobramycin	Novartis		Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)
Ofloxacine	Ofloxacine	Assistance Publique - Hôpitaux de Paris		Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1
Nebcin	Nebcin	University Hospital, Lille		Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 3 drugs in Synergy for Nosocomial Pneumonia due to Pseudomonas Aeruginosa
Assistance Publique - Hôpitaux de Paris · 1 drug in Synergy for Nosocomial Pneumonia due to Pseudomonas Aeruginosa
Generic (originally Daiichi Sankyo/J&J) · 1 drug in Synergy for Nosocomial Pneumonia due to Pseudomonas Aeruginosa
Novartis · 1 drug in Synergy for Nosocomial Pneumonia due to Pseudomonas Aeruginosa
Pfizer · 1 drug in Synergy for Nosocomial Pneumonia due to Pseudomonas Aeruginosa
University Hospital, Lille · 1 drug in Synergy for Nosocomial Pneumonia due to Pseudomonas Aeruginosa

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Synergy for Nosocomial Pneumonia due to Pseudomonas Aeruginosa:

Cite this brief

Drug Landscape (2026). Synergy for Nosocomial Pneumonia due to Pseudomonas Aeruginosa — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/synergy-for-nosocomial-pneumonia-due-to-pseudomonas-aeruginosa. Accessed 2026-06-10.

Synergy for Nosocomial Pneumonia due to Pseudomonas Aeruginosa full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing